AMRN
Pues ahí está
AMARIN WINS EXPANDED USE OF VASCEPA FROM FDA
FDA approved Vascepa as an adjunctive (secondary) therapy to reduce the risk of CV events among adults with elevated TG of 150 mg/dL or higher. Patients must also have either established CV disease or diabetes and two or more additional risk factors for CV disease.